CAR-T cells take on rheumatoid arthritis in Head-to-Head trial

NCT ID NCT06475495

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase I/II trial compares a single dose of CAR-T cell therapy (KYV101) to two doses of rituximab in 13 people with active, treatment-resistant rheumatoid arthritis. The main goals are to check safety and see if the CAR-T treatment can turn off certain immune markers linked to the disease. Participants are followed for 52 weeks.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
CAR-T cell therapy (KYV101) and rituximab
What this could lead to
If successful, this could point toward a new treatment option for people with severe rheumatoid arthritis that hasn't responded to other therapies.
What could go wrong
This is a very early, small trial with only 13 participants, so results may not apply broadly. CAR-T therapy carries risks like cytokine release syndrome and nerve toxicity.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for RHEUMATOID ARTHRITIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Charité - Universitätsmedizin Berlin

    Berlin, State of Berlin, 10117, Germany

More trials for these conditions

Other studies related to the condition(s) this trial covers.